Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Healius Limited ( (AU:HLS) ).
Macquarie Group Limited and its controlled entities have lodged a notice stating they have ceased to be substantial holders in Healius Limited. The filing, signed by Macquarie’s company secretary on 13 April 2026, indicates changes in relevant interests and associations in Healius shares, signalling that Macquarie’s aggregate holding has fallen below the substantial shareholder threshold.
The move alters Healius’s institutional shareholder base and may modestly affect perceptions of the company’s support from major financial investors. While the detailed transaction data are contained in annexures, the notice formally records Macquarie’s changed status and clarifies the relationship of its controlled entities with respect to voting interests in the healthcare group.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$0.80 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is an Australian healthcare company listed on the ASX, operating primarily in diagnostic services and medical centres. The group focuses on pathology, imaging and related health services across Australia, serving both public and private healthcare markets.
YTD Price Performance: -44.75%
Average Trading Volume: 3,428,560
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$363.1M
Find detailed analytics on HLS stock on TipRanks’ Stock Analysis page.